Arming "old guards" with "new dual-targeting weapons"

Lawrence G Lum; Jogender Tushir-Singh

doi:10.1016/j.ccell.2021.04.010

Arming "old guards" with "new dual-targeting weapons"

Cancer Cell. 2021 May 10;39(5):604-606. doi: 10.1016/j.ccell.2021.04.010.

Authors

Lawrence G Lum¹, Jogender Tushir-Singh²

Affiliations

¹ Stem Cell Transplantation Program and Cellular Therapy Program, Division of Oncology/Hematology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA. Electronic address: LGL4F@virginia.edu.
² Laboratory of Novel Biologics, Department of Biochemistry and Molecular Genetics, University of Virginia Cancer Center, Charlottesville, VA, USA. Electronic address: jogi@virginia.edu.

PMID: 33974858
DOI: 10.1016/j.ccell.2021.04.010

Abstract

The long-held paradigm that tumor suppressors are un-targetable in cancer therapy is challenged by a study published in Science. This recent work elegantly describes and characterizes a p53 mutant peptide-selective TCR-mimic antibody and its co-targeting T cell-activating bispecific antibody to eliminate neoantigen-expressing tumors.

Publication types

Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Comment

MeSH terms

Antibodies, Bispecific*
Humans
Neoplasms*
T-Lymphocytes

Substances

Antibodies, Bispecific

Abstract

Publication types

MeSH terms

Substances

Grants and funding